

Curriculum Vitae / Wan-Hee RYU, M.D., Ph.D.

Wan-Hee RYU, M.D., Ph.D.

Clinical Research Professor / Jeonbuk National University Hospital
Division of Rheumatology / Department of Internal Medicine

AFFILIATIONS

Clinical Research Professor / Jeonbuk National University Hospital
Division of Rheumatology / Department of Internal Medicine

EDUCATION

1979 – 1982

Jeonju High School in Jeonju

1982 – 1988

Jeonbuk National University Medical School & obtained M.D. degree

1993 – 1995

Graduate School of Jeonbuk National University & obtained Master of Medical Science

1998 – 2000

Graduate School of Jeonbuk National University & obtained Ph.D. Degree for a thesis entitled "NF- κ B-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation".

PROFESSIONAL EXPERIENCE

Professor, 2011 – present

Division of Rheumatology, Department of Internal Medicine, Jeonbuk National University Hospital.

Director of the internal department, 2015 – present

Jeonbuk National University Hospital and medical school

Associate professor, 2006 – 2011

Curriculum Vitae / Wan-Hee RYU, M.D., Ph.D.

Division of Rheumatology, Department of Internal Medicine, Jeonbuk National University Hospital.

Post-Doc, 2003 – 2005

Associate, Division of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, USA

Assistant professor 2002 – 2006

Department of Internal Medicine, Jeonbuk National University Medical School

Full-time instructor, 2000 – 2002

Department of Internal Medicine, Jeonbuk National University Medical School

Clinical Instructor, 1999 – 2000

Department of Internal Medicine, Jeonbuk National University Hospital

Fellowship, 1998 – 1999

Division of Rheumatology, Department of Internal Medicine, Jeonbuk National University Hospital

Fellowship, 1997 – 1998

Division of Rheumatology, School of Medicine, The Catholic University of Korea, The Center for Rheumatic Diseases in Kang-Nam St. Mary's Hospital

Intern & Resident Training, 1991 – 1997

Department of Internal Medicine, Jeonbuk National University Hospital

Public health doctor, 1988 – 1991

Korea military service

#. M.D. 35777

Speciality of Internal Medicine 4986

Speciality of Rheumatology 52

GCP training : 04-Nov-2014

PUBLICATION LIST

- 1) Not All Green Is Tophi: The Importance of Optimizing Minimum Attenuation and Using a Tin Filter to Minimize Clumpy Artifacts on Foot and Ankle Dual-Energy CT. AJR Am J Roentgenol. 1335-1342, 2020

Curriculum Vitae / Wan-Hee RYU, M.D., Ph.D.

- 2) Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. *Arthritis Res Ther.* 122, 2019
- 3) Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor- α Inhibitors for Ankylosing Spondylitis. *J Clin Rheumatol.* e134-e135, 2019
- 4) Coexistence of systemic lupus erythematosus with Kikuchi-Fujimoto disease involving the salivary gland, initially disguised as lymphoma. *Rheumatology (Oxford).* 58(3):550-553, 2019
- 5) Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea. *J Korean Med Sci.* 33(52):e346, 2018
- 6) Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months. *Int J Rheum Dis.* :1001-1009, 2018
- 7) Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor- α Inhibitors for Ankylosing Spondylitis. *J Clin Rheumatol.* 2018
- 8) Pyoderma gangrenosum masquerading as an ulcer related to antiphospholipid antibodies in a patient with systemic lupus erythematosus. *Lupus.*:2174-2176, 2018
- 9) Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. *Rheumatol Int.*:2233-2242, 2018
- 10) Atorvastatin inhibits osteoclast differentiation by suppressing NF- κ B and MAPK signaling during IL-1 β -induced osteoclastogenesis. *Korean J Intern Med.* 397-406, 2018

Curriculum Vitae / Wan-Hee RYU, M.D., Ph.D.

- 11) Panniculitis, A Rare Presentation of Onset and Exacerbation of Juvenile Dermatomyositis: A Case Report and Literature Review. *Arch Rheumatol.* :367-371, 2017
- 12) Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial. *Clin Ther.* 268-278.e2, 2017
- 13) Occurrence of Ulcerative Colitis in a Patient With Adult-Onset Still's Disease: Coincidence or Correlated. *Arch Rheumatol.* 12:32(3):253-256, 2017
- 14) Relationship between decreased lower extremity muscle mass and knee pain severity in both the general population and patients with knee osteoarthritis: Findings from the KNHANES V 1-2. *PLoS One.* 5:12(3):e0173036. 2017
- 15) Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. *Eur Acad Dermatol Venereol.* :e75-e77, 2017
- 16) Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. *Rheumatol Int.* 36(9):1205-14, 2016
- 17) Back Pain Due to Fracture of a Sacral Syndesmophyte in Ankylosing Spondylitis. *Clin Rheumatol.* (6):330, 2016
- 18) Rapid Progressive Peripheral Ulcerative Keratitis Associated with Longstanding Rheumatoid Arthritis. *J Rheumatol.* 43(10):1909-1910, 2016
- 19) BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function. *Oncogene.* 11:35(6):803-4, 2016

Curriculum Vitae / Wan-Hee RYU, M.D., Ph.D.

- 20) Factors Associated with the Use of Complementary and Alternative Medicine for Korean Patients with Rheumatoid Arthritis, *J Rheumatol.* 42(11):2075-81, 2015
- 21) Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. *BMC Musculoskelet Disord.* 15(1):375, 2014
- 22) Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. *Curr Med Res Opin.* 30(12):2399-408, 2014
- 23) Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study. *Rheumatol Int.*:34(10):1369-78, 2014
- 24) Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF α agents: a retrospective analysis of 49 cases. *Clin Rheumatol.* 31(6):931-6, 2012